Generic Name:
Alectinib
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Alecensaro
Project Line:
Reimbursement Review
Project Number:
PC0092-000
NOC Date:
Details
Strength:
150 mg capsule
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (with CNS metastases)
Funding Request:
As monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib and have CNS metastases
Review Status:
Complete
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued: